Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

Abdollahpour-Alitappeh, M and Lotfinia, M and Gharibi, T and Mardaneh, J and Farhadihosseinabadi, B and Larki, P and Faghfourian, B and Sepehr, KS and Abbaszadeh-Goudarzi, K and Abbaszadeh-Goudarzi, G and Johari, B and Zali, MR and Bagheri, N (2018) Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol.

Full text not available from this repository.
Official URL:


Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody-drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers, have emerged as a promising class of anticancer treatment agents, being one of the fastest growing fields in cancer therapy. The failure of early ADCs led researchers to explore strategies to develop more effective and improved ADCs with lower levels of unconjugated mAbs and more-stable linkers between the drug and the antibody, which show improved pharmacokinetic properties, therapeutic indexes, and safety profiles. Such improvements resulted in the US Food and Drug Administration approvals of brentuximab vedotin, trastuzumab emtansine, and, more recently, inotuzumab ozogamicin. In addition, recent clinical outcomes have sparked additional interest, which leads to the dramatically increased number of ADCs in clinical development. The present review explores ADCs, their main characteristics, and new research developments, as well as discusses strategies for the selection of the most appropriate target antigens, mAbs, cytotoxic drugs, linkers, and conjugation chemistries

Item Type: Article
Uncontrolled Keywords: antibody-drug conjugate, conjugation, cytotoxic small molecules, linkers, monoclonal antibody
Subjects: QZ pathology-Neoplasms
QV pharmacology
QW Microbiology and Immunology
Divisions: Faculty of Medicine
Depositing User: Unnamed user with email
Date Deposited: 23 Dec 2018 08:24
Last Modified: 17 Apr 2019 04:56

Actions (login required)

View Item View Item